Collaboration leads to promising next steps for cancer research
A cancer research company co-founded by an MSU professor has been acquired by the New York biotechnology firm Lodo Therapeutics Corp. in a move that holds the potential for the development of innovative drugs that treat cancerous tumors. The acquisition of Hibiskus BioPharma was announced Sept. 3. Co-founded by André Bachmann of Michigan State University …